Fresenius Kabi received Health Canada's Notice of Compliance (NOC) approval for Iodixanol injection on December 17 for both intravenous and intra-arterial administration With the launch of Iodixanol ...

TORONTO, May 27, 2025 /CNW/ - Fresenius Kabi Canada announces that its ustekinumab biosimilar, developed by Formycon AG, is now commercially available in Canada. Otulfi ™ is indicated for the ...

Fresenius Kabi's ustekinumab biosimilar Otulfi ™ is now commercially available for both subcutaneous and intravenous formulations With this launch, Fresenius Kabi Canada's immunology biosimilar ...

Fresenius Kabi's ustekinumab biosimilar Otulfi ™ is now commercially available for both subcutaneous and intravenous formulations With this launch, Fresenius Kabi Canada's immunology biosimilar ...

In time, a new kind of barcode would emerge: the 2D barcode. This newer technology stores information in the form of two-dimensional shapes like dots, squares and even rectangles, which store even ...

The FDA designated Fresenius Kabi's Otulfi® (ustekinumab-aauz) as an interchangeable biosimilar to the reference product Stelara® (ustekinumab). The FDA designated Fresenius Kabi's Otulfi ...

Director and Head of Commercial, Fresenius Kabi Biopharma, Canada. Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which play an important ...

(RTTNews) - Formycon AG (0W4N.L) along with its commercialization partner Fresenius Kabi, Monday announced that the U.S. Food and Drug Administration designated FYB202/Otulfi as interchangeable ...

LAKE ZURICH, Ill. - Fresenius Kabi, a health care company and part of the Fresenius Group, with a market capitalization of $447 million and a "FAIR" overall financial health rating according to ...

The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. Fresenius Kabi will be fully responsible for the marketing of Vifor’s intravenous iron portfolio in China.

Aurora™ is the automated system that streamlines plasma collection, producing virtually cell-free plasma and providing an improved experience for both operators and donors. The system separates ...